ArticleCase reports in oncological medicine2026
Metastatic Small Cell Neuroendocrine Carcinoma of the Prostate: A Rare and Aggressive Case Report From Bangladesh.
Article in Case reports in oncological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell neuroendocrine carcinoma of the prostate (SCNEC) is a rare but devastatingly aggressive malignancy, carrying a median survival well under 13 months even with multimodal treatment. It may arise de novo or emerge as a treatment-resistance phenotype following androgen deprivation in conventional prostatic adenocarcinoma. A defining and clinically treacherous feature is its failure to elevate serum PSA in proportion to tumour burden-a phenomenon termed the 'PSA paradox'-which routinely delays diagnosis, particularly in resource-limited settings. Case Presentation: We report a 35-year-old Bangladeshi man who presented with obstructive urinary symptoms, constipation and deep pelvic pain. His serum PSA was only 0.77 ng/mL despite a 6.5 × 6.0 × 5.5 cm prostate mass with liver metastases, extensive osteoblastic bone deposits (SUVmax ~18 on 18F-FDG PET/CT), left hydronephrosis and regional lymphadenopathy. Initial TRUS-guided biopsy was reported as Gleason 5 + 5 = 10 adenocarcinoma. Given the PSA-disease burden mismatch, biopsy slides were immediately re-evaluated; haematuria and acute urinary retention necessitated urgent TURP on 4 December 2024, which confirmed a pure de novo SCNEC with diffuse synaptophysin positivity and a Ki-67 index exceeding 60%. GATA3 and p40 were negative. Renal function was confirmed adequate before platinum therapy following palliative TURP(serum creatinine 1.2 mg/dL); etoposide-cisplatin (EP) chemotherapy was administered for six cycles with standard hydration, achieving a marked metabolic response on interim PET/CT. Consolidative pelvic IMRT (55 Gy/20 fractions) followed. Despite this approach, the disease relapsed within 3 months; second-line docetaxel produced no meaningful response. The patient died approximately 11 months from diagnosis. Conclusions: This case underscores the critical importance of recognising the PSA paradox in younger patients with bulky pelvic disease, the indispensable role of a comprehensive IHC panel in confirming the neuroendocrine phenotype and the urgent need for novel therapeutic strategies in this near-universally lethal malignancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.